AbbVie’s Allergan Sues Perrigo to Block Copies of Rosacea Drug

AbbVie’s Allergan and EPI Health said Perrigo’s proposed generic version of Rhofade infringes seven patents for the rosacea treatment.

• Allergan and EPI, a unit of closely held EPI Group, are seeking a court order blocking copies until the patents have expired and cash compensation if copies are made before then, according to complaint filed Monday in federal court in Wilmington, Delaware
• Allergan launched U.S. sales of Rhofade in 2017, complaint says
• EPI Health acquired the rights to Rhofade cream and related intellectual property assets from Aclaris Therapeutics for $55 million in October 2019
• Allergan owns five of ...